🔗 Share this article

While the United States continues making unprecedented changes to its immunization recommendations, an unexpected name has emerged somewhat surprisingly: Tracy Beth Høeg, a US-based physician and epidemiologist who first made her name by questioning coronavirus vaccinations during the global health crisis and has focused upon potential fatalities after COVID-19 immunization in her recent tenure at the FDA.

Planned Changes to Childhood Vaccine Schedule

Agency leaders had intended to reveal radical revisions to the childhood vaccination calendar recently, synchronizing the US with the Danish immunization schedule, according to reports – a significant shift that would put the US out of alignment with many the international standard with little proof for benefit. The planned update has been delayed until the next year.

In place of the director of the vaccine center, Høeg is listed to present at the event. She was recently named temporary leader of the FDA’s drug evaluation center, the fifth person to lead the center this calendar year.

A Shift at the FDA

This interim role may indicate a closer partnership between the drug and vaccine divisions as Høeg and Prasad consolidate power at the agency – and it signals a increased emphasis upon dismantling already-approved immunizations at the FDA.

Høeg has frequently advocated for discontinuing some childhood shot schedules in the US to become more like Denmark, a country with universal health coverage and a citizenry approximately the size of Wisconsin’s.

In her initial comments, she has kept her attention on immunizations – typically the domain of Dr. Prasad, chief of the FDA’s vaccine center – rather than medication approval.

Doubts Over Expertise

Dr. Høeg has little discernible track record in medication creation, approval processes or management, which has been typical for previous heads of the Center for Biologics Evaluation and Research. She has served at the FDA as a top consultant to the FDA chief and the vaccine center since spring.

“She appears not to have the requisite experience” for leading the CDER, remarked Dr. Jonathan Howard. “She’s never run a randomized controlled trial. She is not versed in running a sizeable institution. She lacks background in industry regulation.”

Former heads of the center would “understand laws and regulations and the underlying principles of pharmaceutical innovation”, noted a former acting FDA commissioner. “Clearly, she lacks the type of experience that previous people who ran the center have had.”

The drug center has an immense range of responsibilities at the agency, the former commissioner pointed out.

“Many people just zeroes in on the innovative therapies, but the generic program approves a multitude of off-brand pharmaceuticals. There’s a biosimilars program, over-the-counter program and so forth, and every single one need to be supervised,” she noted. “The thing you overlook, that is the part that I always told people is going to cause problems.”

Furthermore, a substantial management element to the position, which supervises in excess of 5,000 staff members. “It is a huge management job, if you perform it correctly,” she added.

Response and Contentious Initiatives

When asked about concerns about Høeg’s qualifications and whether this appointment represents increased cooperation among FDA leaders on vaccines, a press secretary stated that the “questions are based on incorrect assumptions”.

“Her resume is consistent with the functions of her role,” the representative said, citing the months Dr. Høeg spent guiding the FDA commissioner on “drug safety and regulatory science, including predictive safety algorithms and vaccine surveillance”.

As the temporary head, Dr. Høeg assumes responsibility for the commissioner’s new priority voucher program, a contentious rapid medication authorization process that allegedly concerned her former heads. “How are these medications being chosen for this fast-track system? Who is making the calls?” Howard questioned. “There is a lot of secrecy happening at the regulatory body right now.”

In general, he said, “the FDA seems to be moving towards laxer regulations of pharmaceuticals, except for shots.”

Established Past Work on Vaccines

Concerning immunizations, Høeg has a more established, if problematic, track record, critics have noted. She authored a study using non-validated volunteer-provided data to determine the rate of heart inflammation following Covid immunization. She counseled the state of Florida chief medical officer Joseph Ladapo, who reportedly have modified findings to imply Covid vaccines are pose a greater threat than they are.

Included in her “wish list” for the incoming federal leadership included changing regulations for new vaccines and ending “optional” immunizations, she said following the vote on a podcast. At the agency, Dr. Høeg has according to sources floated the idea of barring young men from obtaining Covid vaccines.

“She is an all-around dogmatist who starts off with her conclusions and tailors the evidence to fit the evidence in a very disingenuous, fraudulent way,” Howard stated.

Gaining Influence and a “Campaign of Retribution”

Dr. Høeg became part of other dissenters, {like|